498 results on '"Collins, Colin C."'
Search Results
102. Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA
103. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer
104. GRB10 sustains AR activity by interacting with PP2A in prostate cancer cells.
105. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
106. Alignment-free clustering of UMI tagged DNA molecules
107. Combinatorial Detection of Conserved Alteration Patterns for Identifying Cancer Subnetworks
108. Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts
109. Abstract 773: A heterochromatin gene signature unveils HP1α mediating neuroendocrine prostate cancer development and aggressiveness
110. Targeting MCT 4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer
111. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
112. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
113. MechRNA: prediction of lncRNA mechanisms from RNA–RNA and RNA–protein interactions
114. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer
115. MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions
116. BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal Mesothelioma
117. Deep Genomic Signature for early metastasis prediction in prostate cancer
118. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model
119. Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
120. Computational identification of micro-structural variations and their proteogenomic consequences in cancer
121. Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer
122. A Genomics Approach to Tumor Gemome Analysis
123. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
124. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
125. Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia
126. HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology
127. Abstract 4420: Elevated glycolytic gene signature in patient-derived neuroendocrine prostate cancer xenograft models and its clinical relevance
128. Abstract 3395: Alternative splicing of the MEAF6 gene promotes neuroendocrine prostate cancer development
129. Clonality Inference from Single Tumor Samples Using Low-Coverage Sequence Data
130. A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents
131. BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
132. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression
133. Metabolic heterogeneity signature of primary treatment-naïve prostate cancer
134. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
135. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
136. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
137. Tumour genomic and microenvironmental heterogeneity as integrated predictors for prostate cancer recurrence: a retrospective study
138. Alignment-free clustering of UMI tagged DNA molecules.
139. The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program.
140. The Proteome of Primary Prostate Cancer.
141. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model
142. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer
143. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA
144. Abstract 118: A comprehensive profile of the genomic architecture of curable prostate cancer
145. Abstract 2921: The retinoblastoma protein regulates hypoxia-inducible factor-1α-mediated transcriptional programs, tumor cell invasiveness, tumor growth and metastasis in human breast cancer cells
146. Transcriptome‐Based Analysis of Molecular Pathways for Clusterin Functions in Kidney Cells
147. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
148. The Proteome of Primary Prostate Cancer
149. The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells
150. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.